Scholarlink

<p>Aminoguanidine (AG) selectively inhibits inducible nitric oxide synthase (iNOS), preventing the toxic overproduction of nitric oxide from arginine during illness. Moreover, it prevents inflammation while preserving its neurotransmitter function. This study aims to fabricate a nanoconjugate of aminoguanidine-gold, coated with modified citrus pectin, and to estimate its efficacy in the OVA-induced asthma rat model. Gold nanoparticles were conjugated to aminoguanidine via EDC/NHS to facilitate amination of the nanoparticle’s surface carboxyl groups. The modified citrus pectin-coated aminoguanidine-conjugated gold (RMCP1) nanoparticles showed a spherical structure with a particle size of 855.5 ± 1.32&#xa0;nm, a surface charge of − 28.1 ± 6.64 mV, and a percent entrapment efficiency of 95.31 ± 3.21% with 77.55 ± 1.49% sustained release in 24&#xa0;h. The diffractogram suggested a transition of crystalline AG and gold nanoparticles to an amorphous form upon coating with modified citrus pectin (MCP). Surface-adsorbed lactose monohydrate RMCP1 (L-RMCP1) exhibited good flowability and minimal inter-particle friction. In-vivo studies suggest improved interleukin-4 (IL-4) levels compared to the asthma control group and antioxidant behaviour. MCP significantly reduced Galactin-3 (Gal-3) in the L-RMCP1-treated asthma group compared to the asthma group. A reduction in leukocyte, monocyte, eosinophil, and neutrophil levels suggests improved efficacy in asthma associated with inflammation. Thus, RMCP1 nanoparticles suppressed the inflammatory response by reducing oxidative stress through the regulation of IL-4 and Galectin-3.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synergistic targeted delivery of aminoguanidine-gold in modified citrus pectin for the management of asthmatic inflammation

  • 期刊论文

  • 发表日期：

    2026年7月31日

查看全文
  • Rishita Dubey,
  • Pravin Shende

摘要

Aminoguanidine (AG) selectively inhibits inducible nitric oxide synthase (iNOS), preventing the toxic overproduction of nitric oxide from arginine during illness. Moreover, it prevents inflammation while preserving its neurotransmitter function. This study aims to fabricate a nanoconjugate of aminoguanidine-gold, coated with modified citrus pectin, and to estimate its efficacy in the OVA-induced asthma rat model. Gold nanoparticles were conjugated to aminoguanidine via EDC/NHS to facilitate amination of the nanoparticle’s surface carboxyl groups. The modified citrus pectin-coated aminoguanidine-conjugated gold (RMCP1) nanoparticles showed a spherical structure with a particle size of 855.5 ± 1.32 nm, a surface charge of − 28.1 ± 6.64 mV, and a percent entrapment efficiency of 95.31 ± 3.21% with 77.55 ± 1.49% sustained release in 24 h. The diffractogram suggested a transition of crystalline AG and gold nanoparticles to an amorphous form upon coating with modified citrus pectin (MCP). Surface-adsorbed lactose monohydrate RMCP1 (L-RMCP1) exhibited good flowability and minimal inter-particle friction. In-vivo studies suggest improved interleukin-4 (IL-4) levels compared to the asthma control group and antioxidant behaviour. MCP significantly reduced Galactin-3 (Gal-3) in the L-RMCP1-treated asthma group compared to the asthma group. A reduction in leukocyte, monocyte, eosinophil, and neutrophil levels suggests improved efficacy in asthma associated with inflammation. Thus, RMCP1 nanoparticles suppressed the inflammatory response by reducing oxidative stress through the regulation of IL-4 and Galectin-3.

Graphical abstract